Christoph Emmerich, a Biochemist by training, carried out his PhD studies in the fields of cancer biology and apoptosis at the German Cancer Research Centre (DKFZ), Heidelberg and at the Imperial College London.

In 2011, Christoph joined the MRC Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU) in Dundee, Scotland where he was involved in several industry-academic collaborations with the main aim to help accelerate the development of future drugs targeting protein kinases and the ubiquitylation system for the improved treatment of disease.

His work is published in high impact factor journals and his projects were based on regulatory mechanisms of the Immune system, with an increasing focus on data quality and integrity standards.